在瘤学中精确准:结合药物的未来
Jia-He Li1, Lei Liu2, Xi-He Zhao1
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, People's Republic of China.
概括
抗体结合药物 (ADC) 和新型抗体-寡核酸结合物为癌症治疗提供了精确的向. 本综述探讨了它们的机制和发展状态,以指导未来的抗瘤策略.
科学领域:
- 在瘤学瘤学.
- 生物技术是生物技术.
- 药物开发 药物开发
背景情况:
- 抗体结合药物 (ADC) 是癌症治疗的重大进展.
- 新兴技术正在推动药物合技术的创新.
- 新的结合体设计挑战了针对性治疗中的现有范式.
研究的目的:
- 阐明伴侣药物的作用机制.
- 审查抗瘤治疗中结合药物的当前发展状况.
- 提出使用结合药物治疗癌症的改进策略.
主要方法:
- 对抗体结合药物和抗体-寡核酸结合物的文献综述.
- 对结构设计和合方式的分析.
- 对药物动力学特性和准精度的评估.
主要成果:
- 抗体-寡核酸合体代表了一种新型的向治疗类型.
- 这些合物表现出精确的向和增强的药理动力学特征.
- 结合技术的进步正在扩大治疗可能性.
结论:
- 结合药物,包括ADC和抗体-寡核酸合物,在瘤学中显示出很大的前景.
- 了解它们的机制和发展对于推进抗瘤策略至关重要.
- 进一步的研究可以优化这些合物,以改善患者的治疗结果.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K


